EUVIMEDEUVIMED entdecken
Delphi-StudieOpen Access · CC BY-NC 4.0

Establishing consensus recommendations for metastatic hormone-sensitive prostate cancer in South Korea: A modified Delphi study

Jae Young Joung iD, In Gab Jeong iD, Sung Gu Kang iD, Young Hwii Ko iD, Kyo Chul Koo iD, Kwang Hyun Kim iD, Myung Ki Kim iD, Soodong Kim iD, Jeong Hyun Kim iD, Sung-Woo Park iD, Jae Young Park iD, Wan Song iD und 16 weitere

Investigative and Clinical Urology · 2025

DOI: 10.4111/icu.20250147 ↗

Kurz gefasst

Delphi-Studie in der Zeitschrift Investigative and Clinical Urology, 2025. Verfasst von Jae Young Joung und 27 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Urological Cancer Center, National Cancer Center, Goyang, Korea. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Androgen Antagonists. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Astellas Pharma US, Pfizer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Consensus is lacking among South Korean urologists on the appropriate treatment of metastatic hormone-sensitive prostate cancer (mHSPC). A modified, Delphi-based consensus on managing mHSPC patients was developed to support clinical decision-making. MATERIALS AND METHODS: Thirty-six questions on mHSPC treatment were developed by an expert committee (five urologists). Nine questions required achievement of consensus (key questions). Twenty-three urologists participated in two rounds of a Delphi survey. Consensus was defined as ≥75% agreement among panelists, with ≥90% agreement representing strong consensus. RESULTS: Eighteen questions (50.0%) reached strong consensus, 15 (41.7%) reached consensus, and three (8.3%) reached no consensus. Eight key questions (88.9%) reached strong consensus and one (11.1%) reached consensus. Consensus was reached on recommending androgen-deprivation therapy (ADT) intensification, irrespective of disease volume or type, with an androgen receptor pathway inhibitor (ARPI) as the preferred option. Not using docetaxel alone with ADT when an ARPI is available for treatment intensification was recommended (strong consensus). For high-volume mHSPC patients with a pathogenic, speckle-type poxvirus and zinc finger protein mutation, ADT+ARPI was recommended over triplet therapy (strong consensus). Panelists recommended regular imaging every 6-12 months if no ARPI reimbursement restrictions exist, but a 3-month interval (per current reimbursement guidelines) otherwise. ADT+ARPI was the most recommended systemic treatment (strong consensus). CONCLUSIONS: This Delphi consensus established local consensus on controversial areas of mHSPC management. The findings offer meaningful perspectives that may help shape future treatment strategies and encourage thoughtful reconsideration of reimbursement criteria to align evidence and clinical practice in South Korea.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsAndrogen AntagonistsHumansMaleDelphi TechniqueRepublic of KoreaNeoplasm MetastasisAndrogen Receptor Antagonists

Stichwörter der Autor:innen

Consensus developmentEvidence-based practiceProstate cancer

Substanzen

Androgen AntagonistsAndrogen Receptor Antagonists

Autor:innen und Institutionen

  • Department of Urology, Urological Cancer Center, National Cancer Center, Goyang, Korea.
  • Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
  • Department of Urology, Korea University College of Medicine, Seoul, Korea.
  • Department of Urology, Ewha Womans University Mokdong Hospital, Seoul, Korea.
  • Department of Urology, Yonsei University College of Medicine, Seoul, Korea.
  • Department of Urology, Ewha Womans University Seoul Hospital, Ewha Womans University College of Medicine, Seoul, Korea.

ORCID-Profile: Jae Young Joung, In Gab Jeong, Sung Gu Kang, Young Hwii Ko, Kyo Chul Koo, Kwang Hyun Kim, Myung Ki Kim, Soodong Kim, Jeong Hyun Kim, Sung-Woo Park, Jae Young Park, Wan Song, Seung Hwan Lee, Seung Il Jung, Jae Hoon Chung, Chang Wook Jeong, Kwan Joong Joo, Seock Hwan Choi, Se Young Choi, Seol Ho Choo, Hong Koo Ha, Sung Kyu Hong, Sung-Hoo Hong, Jeong Hee Hong, Jun Hyuk Hong, Sun Il Kim, Cheol Kwak, Seong Soo Jeon

Förderung

  • Astellas Pharma US
  • Pfizer

Zitieren

APA

Joung, J. Y., Jeong, I. G., Kang, S. G., Ko, Y. H., Koo, K. C., Kim, K. H., Kim, M. K., Kim, S., Kim, J. H., Park, S. W., Park, J. Y., Song, W., Lee, S. H., Jung, S. I., Chung, J. H., Jeong, C. W., Joo, K. J., Choi, S. H., Choi, S. Y., …, & Jeon, S. S. (2025). Establishing consensus recommendations for metastatic hormone-sensitive prostate cancer in South Korea: A modified Delphi study. Investigative and Clinical Urology. https://doi.org/10.4111/icu.20250147

Vancouver

Joung JY, Jeong IG, Kang SG, Ko YH, Koo KC, Kim KH, et al. Establishing consensus recommendations for metastatic hormone-sensitive prostate cancer in South Korea: A modified Delphi study. Investigative and Clinical Urology. 2025. doi:10.4111/icu.20250147

BibTeX
@article{Joung2025,
  author = {Joung, Jae Young and Jeong, In Gab and Kang, Sung Gu and Ko, Young Hwii and Koo, Kyo Chul and Kim, Kwang Hyun and Kim, Myung Ki and Kim, Soodong and Kim, Jeong Hyun and Park, Sung-Woo and Park, Jae Young and Song, Wan and Lee, Seung Hwan and Jung, Seung Il and Chung, Jae Hoon and Jeong, Chang Wook and Joo, Kwan Joong and Choi, Seock Hwan and Choi, Se Young and Choo, Seol Ho and Ha, Hong Koo and Hong, Sung Kyu and Hong, Sung-Hoo and Hong, Jeong Hee and Hong, Jun Hyuk and Kim, Sun Il and Kwak, Cheol and Jeon, Seong Soo},
  title = {Establishing consensus recommendations for metastatic hormone-sensitive prostate cancer in South Korea: A modified Delphi study},
  journal = {Investigative and Clinical Urology},
  year = {2025},
  doi = {10.4111/icu.20250147}
}
Kostenlos starten →